B12019 and Neulasta are formulations of pegfilgrastim, a pegylated form of the granulocyte colony-stimulating factor analog filgrastim, which mitigates the negative effects of chemotherapy on the ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

The acquisition not only expands Accord BioPharma's product offerings, but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales ...

The company had sought approval of plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) in combination with granulocyte colony-stimulating factor (G-CSF) drug pegfilgrastim ...

Accord Healthcare’s Pelgraz could become the first pegfilgrastim biosimilar to be launched in Europe once it is fully approved by regulators. The drug is used to reduce the duration of ...

*Adjusted by: age, gender, stage, tumour type, intention of treatment, CT type and duration, prophylactic G-CSF use, G-CSF use within 72h after CT, baseline biochemistry. This is an ASCO Meeting ...

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration ...